Regeneron Pharmaceuticals News
Here are four more themes where you can put money to work.
Cramer prefers Tiffany over Excorp, likes Lockheed and wants no part of Alliance Fiber Optic Products.
Cramer is not as concerned about tomorrow's labor report as others.
Cliffs Natural Resources is on our watch-list after forming a rounding bottom formation which can be bullish.
Regeneron Pharmaceuticals was a leading decliner within the health care sector, falling $4.06 (-1.4%) to $283.20 on light volume
TheStreet contributor David Sobek offers seven forecasts for biotech stocks in 2014.
Rather than follow the crowd, I want to lead it.
Profit-taking, a weak November, and new competitors make these 3 companies some of the worst performers in the stock market today
Despite discounts on drugs, certain drugmakers look poised to benefit from increased enrollment in Obamacare.
Thinking about investing in Pfizer? Then you need to know these 3 things that could put the company on a collision course with Regeneron, Sanofi, Amgen, and Novartis before 2014.
Bayer submitted a marketing approval application for Eylea in Japan for the treatment of mCNV.
Regeneron Pharmaceuticals (Nasdaq:REGN) has been reiterated by TheStreet Ratings as a hold with a ratings score of C+
3 major biotech stocks hit a 52-week high thanks to Important news flowing in from the EU.
Biotech investing rarely follows a predictable script, so here's four stocks which may surprise even the most experienced investors in 2014.